Liquidia (NASDAQ:LQDA) Reaches New 12-Month High – Here’s Why

Shares of Liquidia Corporation (NASDAQ:LQDA) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $62.37 and last traded at $61.9890, with a volume of 285703 shares changing hands. The stock had previously closed at $60.10.

Key Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia announced that CEO Dr. Roger Jeffs and COO/CFO Michael Kaseta will present a business update at the Jefferies Global Healthcare Conference on June 3. A conference appearance can raise visibility and may signal management confidence in the company’s outlook. Article: Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
• Positive Sentiment: Wall Street sentiment remains constructive, with analysts maintaining a “Moderate Buy” consensus and some firms recently lifting price targets. That supports the stock’s recent strength after a strong earnings report. Article: Liquidia Corporation (NASDAQ:LQDA) Given Average Recommendation of “Moderate Buy” by Analysts
• Neutral Sentiment: Recent insider sales by CEO Roger Jeffs, including another 25,000-share sale, were made under a pre-arranged 10b5-1 plan. The sales may be viewed as routine, but multiple insider disposals can still weigh on investor sentiment. Article: Liquidia (NASDAQ:LQDA) CEO Roger Jeffs Sells 25,000 Shares
• Neutral Sentiment: Director Raman Singh also sold shares recently, adding to the pattern of insider selling. While not necessarily a fundamental red flag, it can create near-term caution for traders. Article: Liquidia (NASDAQ:LQDA) Director Raman Singh Sells 29,494 Shares of Stock

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. BTIG Research raised their price objective on shares of Liquidia from $50.00 to $59.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Needham & Company LLC raised their price objective on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, May 11th. HC Wainwright increased their target price on shares of Liquidia from $55.00 to $67.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Finally, Lifesci Capital upgraded shares of Liquidia to a “strong-buy” rating in a research report on Thursday, March 5th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Liquidia has an average rating of “Moderate Buy” and an average price target of $49.33.

Liquidia Stock Performance

The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The stock’s 50-day moving average is $43.00 and its 200 day moving average is $37.80. The firm has a market cap of $5.61 billion, a P/E ratio of 450.38 and a beta of 0.41.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. The firm’s revenue was up 4187.1% on a year-over-year basis. On average, research analysts predict that Liquidia Corporation will post 2.97 earnings per share for the current year.

Insider Buying and Selling at Liquidia

In other Liquidia news, Director Stephen M. Bloch sold 318,893 shares of Liquidia stock in a transaction on Monday, May 11th. The shares were sold at an average price of $50.23, for a total value of $16,017,995.39. Following the sale, the director directly owned 1,870,042 shares in the company, valued at approximately $93,932,209.66. The trade was a 14.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Raman Singh sold 29,494 shares of Liquidia stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $60.13, for a total transaction of $1,773,474.22. Following the completion of the sale, the director owned 38,755 shares in the company, valued at $2,330,338.15. The trade was a 43.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,127,207 shares of company stock valued at $50,967,227 over the last quarter. 25.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Liquidia

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LQDA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Liquidia by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after buying an additional 1,700 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Liquidia by 10.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after purchasing an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Liquidia by 15.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after purchasing an additional 16,022 shares during the last quarter. Creative Planning increased its stake in shares of Liquidia by 40.7% during the 2nd quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after purchasing an additional 7,765 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Liquidia by 13.4% during the 2nd quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after purchasing an additional 11,111 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).